CY1109882T1 - Νεα αλατα ατορβαστατινης και φαρμακευτικες συνθεσεις που τα περιεχουν - Google Patents

Νεα αλατα ατορβαστατινης και φαρμακευτικες συνθεσεις που τα περιεχουν

Info

Publication number
CY1109882T1
CY1109882T1 CY20101100235T CY101100235T CY1109882T1 CY 1109882 T1 CY1109882 T1 CY 1109882T1 CY 20101100235 T CY20101100235 T CY 20101100235T CY 101100235 T CY101100235 T CY 101100235T CY 1109882 T1 CY1109882 T1 CY 1109882T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
compositions containing
atorvastatin salts
new
new atorvastatin
Prior art date
Application number
CY20101100235T
Other languages
Greek (el)
English (en)
Inventor
János Fischer
Krisztina Vukics
Péter ERDELYI
Béla Hegedüs
Károly Tihanyi
Mónika Vastag
Sándor Levai
Sándorné Balint
Krisztina Lanczos
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of CY1109882T1 publication Critical patent/CY1109882T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20101100235T 2002-03-28 2010-03-11 Νεα αλατα ατορβαστατινης και φαρμακευτικες συνθεσεις που τα περιεχουν CY1109882T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0201083A HUP0201083A2 (hu) 2002-03-28 2002-03-28 Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
EP03730380A EP1490333B1 (en) 2002-03-28 2003-03-27 New atorvastatin salts and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CY1109882T1 true CY1109882T1 (el) 2014-09-10

Family

ID=89980299

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100235T CY1109882T1 (el) 2002-03-28 2010-03-11 Νεα αλατα ατορβαστατινης και φαρμακευτικες συνθεσεις που τα περιεχουν

Country Status (11)

Country Link
EP (1) EP1490333B1 (enExample)
AT (1) ATE455761T1 (enExample)
AU (1) AU2003241060A1 (enExample)
CY (1) CY1109882T1 (enExample)
DE (1) DE60331051D1 (enExample)
DK (1) DK1490333T3 (enExample)
ES (1) ES2339935T3 (enExample)
HU (1) HUP0201083A2 (enExample)
PT (1) PT1490333E (enExample)
SI (1) SI1490333T1 (enExample)
WO (1) WO2003082816A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
US20040248957A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
CA2551549A1 (en) 2003-12-29 2005-07-14 Lek Pharmaceuticals D.D. Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
FR2869539B1 (fr) * 2004-04-29 2008-08-08 Univ Paris Descartes Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
EP3581564A1 (en) * 2004-05-05 2019-12-18 Pfizer Products Inc. Diethylamine salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
WO2006054308A2 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
EP1898922A4 (en) * 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2011089559A1 (en) * 2010-01-22 2011-07-28 Orchid Chemicals And Pharmaceuticals Limited A novel polymorphic form of atorvastatin salts
MX2010011006A (es) * 2010-10-06 2012-04-18 Senosiain S A De C V Lab Nueva sal de un derivado de pirimidina.
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐
WO2013083674A1 (de) * 2011-12-08 2013-06-13 Hexal Ag Neue pharmazeutische statin-zusammensetzung
CN103232398B (zh) * 2012-04-28 2016-04-06 上海科州药物研发有限公司 一种瑞舒伐他汀氨基酸盐及其制备方法和应用
CN105246472B (zh) * 2013-03-15 2018-10-12 武汉朗来科技发展有限公司 含有鸟氨酸和/或门冬氨酸的组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9609872A (pt) * 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
CA2406574C (en) * 2000-04-10 2006-12-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids

Also Published As

Publication number Publication date
ATE455761T1 (de) 2010-02-15
ES2339935T3 (es) 2010-05-27
HUP0201083A2 (hu) 2004-06-28
EP1490333A1 (en) 2004-12-29
PT1490333E (pt) 2010-03-04
SI1490333T1 (sl) 2010-04-30
DK1490333T3 (da) 2010-05-25
HU0201083D0 (enExample) 2002-05-29
WO2003082816A1 (en) 2003-10-09
AU2003241060A1 (en) 2003-10-13
DE60331051D1 (de) 2010-03-11
EP1490333B1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
CY1118225T1 (el) Διαδικασια για την παρασκευη 5-διφαινυλ-4-αμινο-2-μεθυλ πεντανοϊκου οξεος
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
CY1120081T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
DK1265606T3 (da) Celleadhæsionsinhibitorer
CY1108559T1 (el) Αλατα βαλσαρτανης
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
CY1114689T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
BR0308979A (pt) Derivados de indolilmaleimida
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
CY1112550T1 (el) Παραγωγο δικυκλοεστερα
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
TW200635585A (en) Monocyclic substituted methanones
CY1110605T1 (el) Διαδικασια για την παρασκευη ενωσεων πυριμιδινης
EA200401114A3 (ru) Замещённые гидроксиэтиламины
CY1113171T1 (el) Αντιφλεγμονωδεις παραγοντες
DK1490333T3 (da) Nye atorvastatinsalte og farmaceutiske sammensætninger indeholdende dem
CY1118131T1 (el) Φαρμακο δραστικο στο νευροπαθητικο αλγος
CY1109126T1 (el) Βιοτιλιωμενοι εξαδεκασακχαριτες, φαρμακευτικες συνθεσεις και η εφαρμογη τους
CY1105734T1 (el) Nεα προ-φαρμακα του 1-μεθυλο-2-(4-αμιδινοφαινυλαμινομεθυλο)-βενζιμιδαζολ-5-υλιο-καρβοξυλικο οξυ-(ν-2-πυριδυλο-ν-2-υδροξυκαρβονυλαιθυλο)-αμιδιου, η παρασκευη και η χρησιμοποιηση τους ως φαρμακων
CY1111606T1 (el) Διαδικασια διαχωρισμου για to (r)-(-)-2-yδροξy-2- (2-χλωροφαινυλ) οξικο οξυ
BRPI0409095A (pt) processos de sìntese do ácido (2s)-indolina-2-carboxìlico, e aplicação para a sìntese do perindopril
BRPI0416746A (pt) processo de sìntese do perindopril e de seus sais farmaceuticamente aceitáveis